Growth Axis and Secretagogue Research
Growth hormone biology connects hypothalamic control, pituitary hormone release and tissue-level IGF-1 signalling. The distinction matters: a compound that stimulates a short-lived growth hormone pulse is not equivalent to an IGF-1 analogue, and an increase in a blood biomarker is not itself a demonstration of tissue growth. This hub examines receptor systems, assay design and the limits of evidence surrounding research peptides in this category.
The hypothalamic–pituitary growth axis
Hypothalamic growth hormone-releasing hormone (GHRH) promotes pituitary GH secretion, while somatostatin restrains it. Feedback from GH and IGF-1 contributes to regulation. Secretion is pulsatile and influenced by sleep, nutrition, age and sampling time, so isolated hormone measurements can be misleading.
GHRH receptor agonists: sermorelin and CJC-1295
Sermorelin is a GHRH-derived peptide used in receptor and endocrine research. CJC-1295 is used inconsistently as a commercial label, including products described with and without DAC; the precise sequence and modification determine pharmacological interpretation. Researchers should verify compound identity rather than assume all products sold under the name share the same kinetics.
Ghrelin receptor signalling and ipamorelin
Ipamorelin is a growth hormone secretagogue studied in relation to the ghrelin receptor, GHSR1a. This is a different receptor system from GHRH signalling. Experiments should separate receptor activation, downstream calcium or second-messenger responses and actual hormone release in a suitable biological model.
IGF-1 and receptor-level effects
IGF-1 acts through the IGF-1 receptor and related signalling networks, including PI3K–AKT and MAPK pathways. IGF-1 LR3 is an analogue with altered binding characteristics. Cellular proliferation or phosphorylation data cannot establish systemic safety or long-term effects; dose-response relationships and off-target signalling require independent study.
Receptor selectivity and experimental controls
Competitive binding, concentration-response experiments, negative controls and assays for closely related receptors help clarify selectivity. Hormone immunoassays can be affected by cross-reactivity and timing. Researchers should record the peptide sequence, modifications, matrix and detection method before interpreting apparent potency.
Interpreting endocrine research responsibly
An acute GH increase is not a validated proxy for strength, recovery, fat loss or other clinical outcomes. Animal findings may differ across species and sex. Clinical claims require appropriately controlled human evidence, not inference from receptor pharmacology or commercial product descriptions.
Frequently asked research questions
Is ipamorelin a GHRH analogue?
No. Ipamorelin is studied as a ghrelin-receptor-related secretagogue; GHRH analogues act through a different receptor.
Are all CJC-1295 preparations identical?
No. Naming and modifications vary, so sequence and analytical documentation matter.
Does increased GH prove a growth outcome?
No. Hormone release is an intermediate measurement and does not establish longer-term outcomes.
Further reading and source discovery
The following PubMed searches provide access to peer-reviewed literature. Review original papers and their publication dates before drawing conclusions.
Research-only information: Content is for laboratory and scientific context. It is not medical advice, a dosing guide or evidence that research-only materials are safe or effective for human use.